Anoro Ellipta Administration and Key Clinical Information
Anoro Ellipta (umeclidinium 62.5 mcg/vilanterol 25 mcg) should be administered as one inhalation once daily at the same time each day for maintenance treatment of COPD in adults. 1
Administration Details
- Dose: One inhalation once daily using the Ellipta dry powder inhaler
- Delivered dose: 55 mcg umeclidinium/22 mcg vilanterol (from the labeled 62.5/25 mcg)
- Timing: Same time each day for consistency
- Device: Ellipta multi-dose dry powder inhaler, designed for ease of use 2
Absolute Contraindication
Anoro Ellipta is absolutely contraindicated in patients with asthma. 1 This is critical—the combination contains a long-acting beta-agonist (LABA) without an inhaled corticosteroid, and LABAs used alone in asthma increase the risk of asthma-related death, hospitalizations, and intubations.
Common Adverse Effects (≥1% and More Common Than Placebo)
Based on clinical trials with 4,733 subjects over 6 months 1:
Infections:
- Pharyngitis (2%)
- Sinusitis (1%)
- Lower respiratory tract infection (1%)
Gastrointestinal:
- Diarrhea (2%)
- Constipation (1%)
Musculoskeletal:
- Pain in extremity (2%)
- Muscle spasms (1%)
- Neck pain (1%)
General:
- Chest pain (1%)
Postmarketing adverse reactions include palpitations, blurred vision, glaucoma, increased intraocular pressure, hypersensitivity reactions (anaphylaxis, angioedema, urticaria), dysgeusia, tremor, anxiety, dysuria, urinary retention, dysphonia, and paradoxical bronchospasm. 1
Clinical Positioning Based on Guidelines
According to the 2023 Canadian Thoracic Society guidelines 3:
For patients with moderate-to-high symptoms (mMRC ≥2, CAT ≥10) and impaired lung function (FEV₁ <80% predicted):
- LAMA/LABA dual therapy (like Anoro Ellipta) is recommended as initial maintenance therapy (strong recommendation)
- This represents a change from 2019 guidelines, now prioritizing dual bronchodilator therapy upfront based on superior efficacy with similar safety profiles
For high-risk exacerbators (≥2 moderate or ≥1 severe exacerbation in past year):
- Step up to triple therapy (LAMA/LABA/ICS) is recommended
- Anoro Ellipta alone would be insufficient for this population
Important Clinical Warnings
Cardiovascular effects: Use with caution in patients with cardiovascular disorders (coronary insufficiency, arrhythmias, hypertension). The beta-agonist component can cause tachycardia, arrhythmias, and blood pressure changes. 1
Narrow-angle glaucoma: Can worsen symptoms—instruct patients to contact provider immediately if eye pain, blurred vision, or visual halos develop. 1
Urinary retention: Particularly problematic in patients with prostatic hyperplasia or bladder-neck obstruction. Monitor for difficulty or painful urination. 1
Paradoxical bronchospasm: If this occurs, discontinue immediately and institute alternative therapy. 1
Drug interactions: Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase vilanterol exposure—use with caution. 1
Clinical Efficacy Evidence
Anoro Ellipta demonstrates superior lung function improvements compared to monotherapy components and tiotropium monotherapy 2, 4. In real-world studies, it shows higher medication adherence (mean PDC 0.44 vs 0.37 for tiotropium) and lower COPD-related medical costs 5. The combination is effective in both current and former smokers 6, addressing a key clinical question about bronchodilator efficacy across smoking status.
The once-daily dosing with the Ellipta device improves treatment compliance compared to twice-daily regimens, which is clinically significant given that adherence is associated with reduced mortality, hospitalizations, and costs. 2, 5